Genmab A/S (NASDAQ:GMAB) Sets New 52-Week Low - Here's What Happened

Genmab A/S (NASDAQ:GMAB - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $19.00 and last traded at $19.28, with a volume of 162448 shares changing hands. The stock had previously closed at $19.67.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. BMO Capital Markets reaffirmed an "outperform" rating and issued a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Sanford C. Bernstein upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Friday, December 20th. Finally, HC Wainwright reissued a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $45.20.

Genmab A/S Stock Performance

The company has a market capitalization of $12.81 billion, a PE ratio of 18.79, a P/E/G ratio of 0.55 and a beta of 0.96. The stock has a 50 day moving average price of $20.93 and a two-hundred day moving average price of $23.52.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). The business had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period in the previous year, the business posted $0.47 EPS. Sell-side analysts predict that Genmab A/S will post 1.25 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

Several institutional investors and hedge funds have recently modified their holdings of the business. Legacy Wealth Asset Management LLC raised its holdings in Genmab A/S by 1.1% during the third quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company's stock valued at $1,097,000 after buying an additional 471 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Genmab A/S by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock valued at $186,000 after acquiring an additional 827 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after purchasing an additional 1,051 shares during the last quarter. Eagle Asset Management Inc. boosted its position in Genmab A/S by 10.0% during the third quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company's stock worth $285,000 after purchasing an additional 1,121 shares during the period. Finally, Grandfield & Dodd LLC grew its holdings in Genmab A/S by 4.2% during the fourth quarter. Grandfield & Dodd LLC now owns 33,733 shares of the company's stock valued at $704,000 after purchasing an additional 1,370 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.